Co-Authors
This is a "connection" page, showing publications co-authored by Suzanne Conzen and Rita Nanda.
Connection Strength
1.189
-
A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer. Springerplus. 2016; 5(1):947.
Score: 0.491
-
Carboplatin, gemcitabine, and mifepristone for advanced breast and recurrent/persistent epithelial ovarian cancer. Breast Cancer Res Treat. 2025 Oct; 213(3):347-354.
Score: 0.231
-
High tumor glucocorticoid receptor expression in early-stage, triple-negative breast cancer is associated with increased T-regulatory cell infiltration. Breast Cancer Res Treat. 2025 Feb; 209(3):563-572.
Score: 0.220
-
Gene expression of peripheral blood cells reveals pathways downstream of glucocorticoid receptor antagonism and nab-paclitaxel treatment. Pharmacogenet Genomics. 2014 Sep; 24(9):451-8.
Score: 0.108
-
Single-Cell Profiling Reveals a Treg-Rich, NK Cell-Depleted Immune Microenvironment in Triple-Negative Breast Cancer with High-Glucocorticoid Receptor Expression. Breast Cancer (Dove Med Press). 2026; 18:569936.
Score: 0.061
-
A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer. Breast Cancer Res Treat. 2025 May; 211(1):111-119.
Score: 0.056
-
Phase II trial of temsirolimus in patients with metastatic breast cancer. Breast Cancer Res Treat. 2012 Nov; 136(2):355-63.
Score: 0.023